Local view for "https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1334"
Predicate | Value (sorted: none) |
---|---|
rdf:type | |
rdf:type | |
rdfs:label | |
?:Evidence_type | |
?:Evidence_assump_list_id |
"230"
|
?:Evidence_enzyme_system | |
?:claim_assumed_valid_for_evidence_application_evidence_1076 | |
dc:creator | |
dc:date |
"06/20/2009 15:52:09"
|
?:content |
"route of administration: oral
study duration: single 25mg dose of thioridazine
population: 19 healthy male subjects: 6 slow and 13 rapid hydroxylators of debrisoquin
ages: 19 - 41
Quote:
"Slow hydroxylators of debrisoquin obtained higher serum levels of thioridazine with a 2.4-fold higher Cmax and a 4.5-fold larger AUC(0-infinity) associated with a twofold longer half-life compared with that of rapid hydroxylators.""
|
rdfs:seeAlso |
All properties reside in the graph file:///home/swish/src/ClioPatria/guidelines/dikb.ttl
The resource appears as object in one triple:
{ thioridazine_primary_total_clearance_enzyme_cyp2d6, <http://purl.org/swan/1.2/swan-commons#citesAsSupportingEvidence>, evidence_1076 }